Stocks
Global Blood Therapeutics Financial Statements (GBT) |
||||||||||
| Global Blood Therapeuticssmart-lab.ru | % | 2017 | 2018 | 2019 | 2020 | 2021 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 27.02.2018 | 27.02.2019 | 26.02.2020 | 24.02.2021 | 23.02.2022 | 08.08.2022 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.000 | 0.000 | 2.11 | 123.8 | 194.7 | 234.9 | |||
| Operating Income, bln rub | -119.2 | -182.7 | -281.3 | -243.2 | -287.1 | -297.4 | ||||
| EBITDA, bln rub | ? | -115.4 | -169.6 | -256.8 | -226.9 | -278.5 | -288.4 | |||
| Net profit, bln rub | ? | -117.0 | -174.2 | -266.8 | -247.6 | -303.1 | -326.4 | |||
| OCF, bln rub | ? | -93.0 | -135.4 | -194.4 | -211.9 | -256.8 | -249.4 | |||
| CAPEX, bln rub | ? | 3.10 | 4.82 | 3.46 | 8.75 | 3.23 | 1.95 | |||
| FCF, bln rub | ? | -96.1 | -140.2 | -197.9 | -220.6 | -260.0 | -251.3 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 119.2 | 182.7 | 291.6 | 366.0 | 479.1 | 529.7 | ||||
| Cost of production, bln rub | 0.000 | 0.000 | 0.048 | 1.99 | 3.32 | 4.45 | ||||
| R&D, bln rub | 87.8 | 131.3 | 174.6 | 155.1 | 212.1 | 227.1 | ||||
| Interest expenses, bln rub | 0.000 | 0.000 | 0.000 | 9.81 | 15.5 | 24.7 | ||||
| Assets, bln rub | 356.7 | 617.6 | 796.1 | 724.0 | 939.2 | 870.4 | ||||
| Net Assets, bln rub | ? | 318.8 | 572.8 | 578.7 | 416.2 | 196.4 | 118.4 | |||
| Debt, bln rub | 0.000 | 0.000 | 75.4 | 153.7 | 659.6 | 658.4 | ||||
| Cash, bln rub | 314.8 | 477.5 | 610.0 | 560.9 | 684.7 | 517.2 | ||||
| Net debt, bln rub | -314.8 | -477.5 | -534.5 | -407.2 | -25.1 | 141.2 | ||||
| Ordinary share price, rub | 39.4 | 41.1 | 79.5 | 43.3 | 29.3 | 67.5 | ||||
| Number of ordinary shares, mln | 42.3 | 51.2 | 58.3 | 61.3 | 62.9 | 65.6 | ||||
| Market cap, bln rub | 1 665 | 2 100 | 4 636 | 2 656 | 1 842 | 4 428 | ||||
| EV, bln rub | ? | 1 351 | 1 622 | 4 101 | 2 249 | 1 817 | 4 569 | |||
| Book value, bln rub | 319 | 573 | 579 | 416 | 196 | 118 | ||||
| EPS, rub | ? | -2.76 | -3.41 | -4.57 | -4.04 | -4.82 | -4.98 | |||
| FCF/share, rub | -2.27 | -2.74 | -3.39 | -3.60 | -4.13 | -3.83 | ||||
| BV/share, rub | 7.53 | 11.2 | 9.92 | 6.79 | 3.12 | 1.80 | ||||
| EBITDA margin, % | ? | -12 184% | -183.3% | -143.0% | -122.8% | |||||
| Net margin, % | ? | -12 655% | -200.0% | -155.6% | -139.0% | |||||
| FCF yield, % | ? | -5.77% | -6.68% | -4.27% | -8.31% | -14.1% | -5.68% | |||
| ROE, % | ? | -36.7% | -30.4% | -46.1% | -59.5% | -154.3% | -275.7% | |||
| ROA, % | ? | -32.8% | -28.2% | -33.5% | -34.2% | -32.3% | -37.5% | |||
| P/E | ? | -14.2 | -12.1 | -17.4 | -10.7 | -6.08 | -13.6 | |||
| P/FCF | -17.3 | -15.0 | -23.4 | -12.0 | -7.08 | -17.6 | ||||
| P/S | ? | 2 199 | 21.5 | 9.46 | 18.9 | |||||
| P/BV | ? | 5.22 | 3.67 | 8.01 | 6.38 | 9.38 | 37.4 | |||
| EV/EBITDA | ? | -11.7 | -9.57 | -16.0 | -9.91 | -6.52 | -15.8 | |||
| Debt/EBITDA | 2.73 | 2.82 | 2.08 | 1.79 | 0.09 | -0.49 | ||||
| R&D/CAPEX, % | 2 832% | 2 722% | 5 045% | 1 772% | 6 562% | 11 652% | ||||
| CAPEX/Revenue, % | 164.1% | 7.07% | 1.66% | 0.83% | ||||||
| Global Blood Therapeutics shareholders | ||||||||||
